The prognostic value of CDKN2A hypermethylation in colorectal cancer: A meta-analysis

British Journal of Cancer

Volumn 108, Issue 12, 2013, Pages 2542-2548

  Xing, X ^a   Cai, W ^b   Shi, H ^a   Wang, Y ^c   Li, M ^a,c   Jiao, J ^a,c   Chen, M ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; META ANALYSIS; METHYLATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TUMOR LOCALIZATION;

CARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84879691871     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.251     Document Type: Article

References (29)

1. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68: 8541-8546.
2. Bihl MP, Foerster A, Lugli A, Zlobec I (2012) Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med 10: 173.
3. Chen SP, Wu CC, Huang SY, Kang JC, Chiu SC, Yang KL, Pang CY (2012) b-Catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients. Genet Test Mol Biomarkers 16: 1277-1281.
4. Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130: 223-233.
5. Draht MX, Riedl RR, Niessen H, Carvalho B, Meijer GA, Herman JG, van Engeland M, Melotte V, Smits KM (2012) Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics 4: 179-194.
6. Egger M, Davey Smith G, Schneider M, Minder C (1997a) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
7. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G (1997b) Language bias in randomised controlled trials published in English and German. Lancet 350: 326-329.
8. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750.
9. Esteller M, González S, Risques RA, Marcuello E, Mangues R, Germà JR, Herman JG, Capellà G, Peinado MA (2001) K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19: 299-304.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101: 403-408.
12. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, Munakata A (2006) Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 21: 1334-1339.
13. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
14. Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS (2010) Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 17: 1767-1776.
15. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT, Cheng AL (1999) Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 57: 149-156.
16. Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G (2003) Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 10: 935-938.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097.
19. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
20. Rayess H, Wang MB, Srivatsan ES (2012) Cellular senescence and tumor suppressor gene p16. Int J Cancer 130: 1715-1725.
21. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129: 837-845.
22. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719.
23. Shen L, Catalano PJ, Benson 3rd AB, O'Dwyer P, Hamilton SR, Issa JP (2007) Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 13: 6093-6098.
24. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S (2011a) Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 128: 1080-1094.
25. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S (2011b) MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22: 301-309.
26. Tada T, Watanabe T, Kazama S, Kanazawa T, Hata K, Komuro Y, Nagawa H (2003) Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology 50: 1756-1760.
27. Veganzones-de-Castro S, Rafael-Fernández S, Vidaurreta- Lázaro M, de-la-Orden V, Mediero-Valeros B, Fernández C, Maestro-de las Casas ML (2012) p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig 104: 111-117.
28. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ (2003) Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21: 3729-3736.
29. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371.